H49.812 Kearns-Sayre syndrome, left eye

Name of the Condition

• Kearns-Sayre syndrome, left eye

Summary

Kearns-Sayre syndrome is a rare mitochondrial disorder characterized by progressive external ophthalmoplegia (weakness of the eye muscles), pigmentary retinopathy, and cardiac conduction defects. This specific code applies to manifestations affecting the left eye. The condition typically presents before age 20 and may involve systemic manifestations such as ataxia, hearing loss, or endocrine abnormalities. It is caused by deletions in mitochondrial DNA and follows a progressive course.

Causes

Kearns-Sayre syndrome is caused by large deletions in mitochondrial DNA, which disrupt energy production in cells. These deletions are usually sporadic and not inherited from parents. The exact trigger for these deletions is not fully understood, but they result in impaired mitochondrial function affecting multiple organ systems, including the ocular structures.

Risk Factors

• Age of onset (typically before 20 years)
• Sporadic mitochondrial DNA deletions
• Family history of mitochondrial disorders (rare)

Symptoms

• Progressive external ophthalmoplegia (eye muscle weakness) affecting the left eye
• Pigmentary retinopathy (retinal changes) in the left eye
• Cardiac conduction defects (e.g., heart block)
• Ataxia (loss of coordination)
• Hearing loss
• Endocrine abnormalities (e.g., diabetes, thyroid issues)
• Short stature
• Cognitive impairment (in some cases)

Diagnosis

Diagnosis is based on clinical features (ophthalmoplegia, retinopathy, cardiac conduction defects) and confirmed by genetic testing for mitochondrial DNA deletions. Additional tests may include electrocardiograms (ECG) to assess cardiac function, brain imaging (MRI/CT) to evaluate neurological involvement, and blood tests to check for systemic abnormalities. Ophthalmologic evaluations are critical to document eye-specific manifestations.

Treatment Options

Treatment focuses on managing symptoms and preventing complications. This may include cardiac monitoring (e.g., pacemakers for heart block), physical therapy for ataxia, hearing aids for hearing loss, and endocrine management for related abnormalities. Eye-specific care may involve corrective lenses or surgery for strabismus, though no cure exists for the underlying mitochondrial defect.

Prognosis and Follow-Up

Kearns-Sayre syndrome follows a progressive course, with symptoms worsening over time. Prognosis depends on the severity of systemic involvement, particularly cardiac and neurological complications. Regular follow-up with a multidisciplinary team (neurologist, cardiologist, ophthalmologist) is essential to monitor disease progression and adjust management as needed.

Complications

• Severe cardiac conduction defects (e.g., complete heart block)
• Respiratory failure due to muscle weakness
• Neurological decline (e.g., ataxia, cognitive impairment)
• Vision loss from retinopathy
• Endocrine dysfunction (e.g., diabetes, thyroid disorders)

Lifestyle & Prevention

No specific prevention exists, as the condition is caused by sporadic genetic mutations. Lifestyle modifications may include regular exercise to maintain mobility, a balanced diet to support overall health, and avoiding medications that could exacerbate mitochondrial dysfunction (e.g., certain anesthetics). Genetic counseling may be recommended for families, though inheritance risk is low.

When to Seek Professional Help

Seek immediate medical attention for symptoms like sudden vision changes, chest pain, fainting, or difficulty breathing, which may indicate cardiac or respiratory complications. Regular follow-up is advised for monitoring of progressive symptoms, especially cardiac or neurological changes.

Tips for Medical Coders

Use this code for Kearns-Sayre syndrome with left eye involvement. Document the eye-specific manifestation clearly in the medical record to support coding. Ensure differentiation from bilateral or right eye presentations when applicable. Verify that the diagnosis aligns with clinical criteria for Kearns-Sayre syndrome, including mitochondrial DNA testing if available, to confirm specificity.